Effekt og sikkerhet av Nemtabrutinib (MK-1026) hos deltakere med hematologiske maligniteter (MK-1026-003)
En fase 2-studie for å evaluere effektiviteten og sikkerheten til MK-1026 hos deltakere med hematologiske maligniteter
The purpose of this study is to evaluate the safety and efficacy of nemtabrutinib (formerly ARQ 531) in participants with hematologic malignancies of chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL), Richter's transformation, marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), follicular lymphoma (FL), and Waldenström's macroglobulinemia (WM).
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Detaljert beskrivelse
This study will be performed in 2 parts: Dose Escalation and Confirmation (Part 1) and Cohort Expansion (Part 2). Following determination of the recommended phase 2 dose (RP2D) in Part 1, the study plans to proceed with Part 2 using 8 disease-specific expansion cohorts (Cohorts A to H).
Studietype
Studietype
Registrering (Antatt)
Registrering
Fase
Fase
- Fase 2
Kontakter og plasseringer
Studiekontakt
Studiekontakt
- Navn: Toll Free Number
- Telefonnummer: 1-888-577-8839
- E-post: Trialsites@msd.com
Studiesteder
-
-
-
Caba, Argentina, C1114AAN
- Rekruttering
- FUNDALEU ( Site 0104)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: 5411 48771046
-
Córdoba, Argentina, X5016KEH
- Rekruttering
- Hospital Privado Universitario de Córdoba ( Site 0107)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +541569634187
-
Mendoza, Argentina, M5500AYB
- Fullført
- Fundacion Centro Oncologico de Integración Regional-Medical Oncology ( Site 0110)
-
-
Buenos Aires
-
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina, C1118AAT
- Rekruttering
- Hospital Aleman ( Site 0102)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +541148277000
-
-
Buenos Aires F.D.
-
Buenos Aires, Buenos Aires F.D., Argentina, C1431FWO
- Rekruttering
- Centro de Educación Médica e Investigaciones Clínicas (CEMIC) ( Site 0103)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +541152990247
-
-
Santa Fe Province
-
Rosario, Santa Fe Province, Argentina, S2000DEJ
- Rekruttering
- Fundacion Estudios Clinicos ( Site 0112)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +54 0341 238 4171
-
-
-
-
New South Wales
-
Sydney, New South Wales, Australia, 2747
- Fullført
- Nepean Hospital-Nepean Cancer Care Centre ( Site 0204)
-
-
Victoria
-
Box Hill, Victoria, Australia, 3128
- Rekruttering
- Box Hill Hospital ( Site 0203)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +611300342255
-
-
Western Australia
-
Nedlands, Western Australia, Australia, 6009
- Rekruttering
- Sir Charles Gairdner Hospital ( Site 0200)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +61864573333
-
-
-
-
-
Rio de Janeiro, Brasil, 20231-050
- Rekruttering
- Instituto Nacional do Cancer Jose Alencar Gomes da Silva INCA ( Site 0300)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +552132076564
-
São Paulo, Brasil, 01321-001
- Rekruttering
- Hospital Paulistano - Amil Clinical Research ( Site 0311)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +551130161340
-
São Paulo, Brasil, 01321-001
- Aktiv, ikke rekrutterende
- BP - A Beneficencia Portuguesa de São Paulo ( Site 0302)
-
-
São Paulo
-
São Paulo, São Paulo, Brasil, 05403-000
- Rekruttering
- Hospital das Clinicas FMUSP-Pesquisa Clínica Hematologia ( Site 0303)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: 551145737543
-
-
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 5G2
- Rekruttering
- Arthur J.E. Child Comprehensive Cancer Centre ( Site 0401)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: 4035213723
-
-
Ontario
-
Ottawa, Ontario, Canada, K1H 8L6
- Rekruttering
- The Ottawa Hospital ( Site 0404)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: 613 737-7700
-
Toronto, Ontario, Canada, M5G 2M9
- Rekruttering
- Princess Margaret Cancer Centre-Division of Medical Oncology and Hematology ( Site 0406)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: 416-946-2827
-
-
Quebec
-
Montreal, Quebec, Canada, H3T 1E2
- Rekruttering
- Jewish General Hospital ( Site 0400)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: 5143408222 x 24572
-
Montreal, Quebec, Canada, H1T 2M4
- Rekruttering
- CIUSSS de l Est de L Ile de Montreal - Hopital Maisonneuve-Rosemont ( Site 0403)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: 5142523400
-
-
-
-
Central Jutland
-
Aarhus N, Central Jutland, Danmark, 8200
- Fullført
- Aarhus University Hospital ( Site 0702)
-
-
North Denmark
-
Aalborg, North Denmark, Danmark, 9000
- Rekruttering
- Aalborg Universitetshospital ( Site 0703)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +45 97660000
-
-
Region Sjælland
-
Koege, Region Sjælland, Danmark, 4600
- Rekruttering
- Sjællands Universitetshospital Køge ( Site 0701)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +45 46323200
-
-
Region Syddanmark
-
Odense C, Region Syddanmark, Danmark, 5000
- Fullført
- Odense University Hospital ( Site 0705)
-
-
-
-
Arkansas
-
Springdale, Arkansas, Forente stater, 72762
- Rekruttering
- Highlands Oncology Group ( Site 2728)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: 479-872-8130
-
-
California
-
La Jolla, California, Forente stater, 92093-0698
- Rekruttering
- University of California San Diego Moores Cancer Center ( Site 2717)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: 858-534-5201
-
Torrance, California, Forente stater, 90502
- Fullført
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA-Hematology and Medical Oncology ( Site 2724)
-
-
Colorado
-
Denver, Colorado, Forente stater, 80218
- Rekruttering
- Colorado Blood Cancer Institute ( Site 2726)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: 720-754-4800
-
-
Kentucky
-
Louisville, Kentucky, Forente stater, 40202
- Fullført
- The University of Louisville, James Graham Brown Cancer Center ( Site 2729)
-
-
Minnesota
-
Rochester, Minnesota, Forente stater, 55905
- Aktiv, ikke rekrutterende
- Mayo Clinic - Rochester ( Site 2706)
-
-
New Jersey
-
East Brunswick, New Jersey, Forente stater, 08816
- Rekruttering
- Astera Cancer Care ( Site 2732)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: 732-672-6405
-
Hackensack, New Jersey, Forente stater, 07601
- Rekruttering
- John Theurer Cancer Center at Hackensack University Medical Center ( Site 2704)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: 551-996-3003
-
-
North Dakota
-
Fargo, North Dakota, Forente stater, 58102
- Fullført
- Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 2708)
-
-
Texas
-
Dallas, Texas, Forente stater, 75390
- Rekruttering
- UT Southwestern-Harold C. Simmons Cancer Center ( Site 2730)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: 972-695-9450
-
-
Washington
-
Spokane, Washington, Forente stater, 99208
- Rekruttering
- Medical Oncology Associates (Summit Cancer Centers) ( Site 2710)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: 509-462-2273
-
-
-
-
-
Paris, Frankrike, 75010
- Rekruttering
- Hopital Saint Louis ( Site 0805)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +33142499236
-
-
Alpes-Maritimes
-
Nice, Alpes-Maritimes, Frankrike, 06202
- Rekruttering
- Centre Hospitalier Universitaire de Nice - Hôpital l'Archet ( Site 0810)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +33 4 92 03 57 85
-
-
Auvergne-Rhône-Alpes
-
Pierre-Bénite, Auvergne-Rhône-Alpes, Frankrike, 69495
- Rekruttering
- Centre Hospitalier Lyon-Sud ( Site 0804)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +33478864348
-
-
Bouches-du-Rhone
-
Marseille, Bouches-du-Rhone, Frankrike, 13009
- Rekruttering
- Institut Paoli-Calmettes ( Site 0803)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +33491223537
-
-
Yvelines
-
Le Chesnay, Yvelines, Frankrike, 78150
- Fullført
- Centre Hospitalier de Versailles ( Site 0809)
-
-
-
-
-
Dublin, Irland, Dublin 9
- Rekruttering
- Beaumont Hospital ( Site 2900)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +35318092010
-
Limerick, Irland, V94 F858
- Aktiv, ikke rekrutterende
- University Hospital Limerick ( Site 2903)
-
-
-
-
-
Afula, Israel, 1834111
- Rekruttering
- Ha Emek Medical Center ( Site 1305)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: 972-46494052
-
Beersheba, Israel, 8410101
- Rekruttering
- Soroka Medical Center ( Site 1307)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +97286403827
-
Haifa, Israel, 3109601
- Rekruttering
- Rambam Medical Center ( Site 1301)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +97247772547
-
Jerusalem, Israel, 9112001
- Rekruttering
- Hadassah Ein Karem Jerusalem ( Site 1300)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +97226778180
-
Ramat Gan, Israel, 5262001
- Rekruttering
- Chaim Sheba Medical Center ( Site 1302)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +97235308401
-
Rehovot, Israel, 76100
- Rekruttering
- Kaplan Medical Center ( Site 1304)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +97289441726
-
Tel Aviv, Israel, 6423906
- Rekruttering
- Sourasky Medical Center ( Site 1303)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +97236973782
-
-
-
-
-
Bari, Italia, 70124
- Fullført
- Istituto Tumori Giovanni Paolo II ( Site 1409)
-
Bologna, Italia, 40138
- Rekruttering
- A.O. Universitaria Policlinico S. Orsola-Malpighi ( Site 1400)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +390516363680
-
Brescia, Italia, 25123
- Rekruttering
- ASST Spedali Civili di Brescia ( Site 1408)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +39 0303996416
-
Milan, Italia, 20132
- Rekruttering
- IRCCS Ospedale San Raffaele ( Site 1402)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: 00390226434797
-
Naples, Italia, 80131
- Rekruttering
- Istituto Nazionale Tumori IRCCS Fondazione Pascale ( Site 1403)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +39 0815903 382
-
Pavia, Italia, 27100
- Rekruttering
- Fondazione IRCCS Policlinico San Matteo ( Site 1407)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +39 0382503084
-
Reggio Emilia, Italia, 42123
- Rekruttering
- IRCCS - Arcispedale Santa Maria Nuova ( Site 1405)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +39 0522295654
-
Roma, Italia, 00161
- Fullført
- Policlinico Umberto I ( Site 1404)
-
-
-
-
Anhui
-
Hefei, Anhui, Kina, 230071
- Aktiv, ikke rekrutterende
- Anhui Provincial Hospital ( Site 2808)
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Kina, 100191
- Rekruttering
- Peking University Third Hospital-Hematology ( Site 2827)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: 010-82266699
-
-
Chongqing Municipality
-
Chongqing, Chongqing Municipality, Kina, 400072
- Aktiv, ikke rekrutterende
- The Second Affiliated Hospital of Chongqing Medical University ( Site 2825)
-
-
Guangdong
-
Guangzhou, Guangdong, Kina, 510060
- Aktiv, ikke rekrutterende
- Sun Yat-sen University Cancer Center-Internal Medicine ( Site 2824)
-
-
Guangxi
-
Liuzhou, Guangxi, Kina, 545006
- Rekruttering
- Liuzhou People's Hospital ( Site 2817)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +8607722662950
-
Nanning, Guangxi, Kina, 530028
- Rekruttering
- Guangxi Medical University Cancer Hospital ( Site 2814)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +8607715323174
-
-
Henan
-
Zhengzhou, Henan, Kina, 450008
- Rekruttering
- Henan Cancer Hospital-hematology department ( Site 2802)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: 0371-65588007
-
-
Hubei
-
Wuhan, Hubei, Kina, 430022
- Rekruttering
- Wuhan Union Hospital ( Site 2816)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +8618627091655
-
-
Hunan
-
Changsha, Hunan, Kina, 410011
- Rekruttering
- The Second Xiangya Hospital of Central South University ( Site 2820)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +8613975806137
-
Changsha, Hunan, Kina, 410013
- Rekruttering
- Hunan Cancer Hospital ( Site 2822)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: 0731-88651669
-
-
Jiangsu
-
Nanjing, Jiangsu, Kina, 210029
- Rekruttering
- Jiangsu Province Hospital ( Site 2823)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: 025-86211033
-
Xuzhou, Jiangsu, Kina, 221000
- Fullført
- The Affiliated Hospital of Xuzhou Medical College ( Site 2818)
-
-
Jiangxi
-
Nanchang, Jiangxi, Kina, 330006
- Rekruttering
- The First Affiliated Hospital of Nanchang University ( Site 2815)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: 13970038386
-
-
Jilin
-
Changchun, Jilin, Kina, 130021
- Rekruttering
- The First Hospital of Jilin University-Hematology ( Site 2803)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: 0431-88786014
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Kina, 200032
- Rekruttering
- Fudan University Shanghai Cancer Center ( Site 2801)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +8602164175590
-
Shanghai, Shanghai Municipality, Kina, 200040
- Rekruttering
- Huashan Hospital, Fudan University ( Site 2821)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: 021-52889999
-
-
Sichuan
-
Chengdu, Sichuan, Kina, 610041
- Rekruttering
- West China Hospital Sichuan University ( Site 2810)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +86028-85422114
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, Kina, 301617
- Rekruttering
- Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Unio ( Site 2800)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +8615900265415
-
-
Zhejiang
-
Hangzhou, Zhejiang, Kina, 310002
- Rekruttering
- The First Affiliated Hospital, Zhejiang University ( Site 2826)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: 057187236114
-
-
-
-
Lesser Poland Voivodeship
-
Krakow, Lesser Poland Voivodeship, Polen, 30-727
- Rekruttering
- Pratia MCM Krakow ( Site 1601)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: 48 12 2954135
-
-
Lower Silesian Voivodeship
-
Wroclaw, Lower Silesian Voivodeship, Polen, 50-367
- Fullført
- Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wrocławiu ( Site 1606)
-
-
Masovian Voivodeship
-
Warsaw, Masovian Voivodeship, Polen, 02-781
- Rekruttering
- Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Kilinka Onkologii I Hematologii ( Site 1608)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +48225462223
-
-
Opole Voivodeship
-
Opole, Opole Voivodeship, Polen, 45-061
- Fullført
- Szpital Wojewódzki w Opolu-Hematology Department ( Site 1607)
-
-
Pomeranian Voivodeship
-
Gdynia, Pomeranian Voivodeship, Polen, 81-519
- Fullført
- Szpitale Pomorskie Sp. z o.o. ( Site 1600)
-
-
-
-
-
Brasov, Romania, 500052
- Rekruttering
- Centrul de Diagnostic si Tratament Oncologic Brasov ( Site 1802)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: 0729075567
-
Iași, Romania, 700483
- Rekruttering
- Institutul Regional de Oncologie Iasi ( Site 1801)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: 40374278811
-
-
Bucharest
-
Bucharest, Bucharest, Romania, 030171
- Rekruttering
- Spitalul Clinic Colțea ( Site 1805)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: 0040213874100
-
-
Constanța County
-
Ovidiu, Constanța County, Romania, 905900
- Fullført
- Ovidius Clinical Hospital ( Site 1804)
-
-
-
-
-
Alicante, Spania, 03010
- Rekruttering
- Hospital General Universitario de Alicante ( Site 2007)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: 965 93 30 00
-
Barcelona, Spania, 08035
- Rekruttering
- Hospital Universitari Vall d'Hebron ( Site 2001)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +34934893806
-
Madrid, Spania, 28041
- Rekruttering
- Hospital Universitario 12 de Octubre ( Site 2003)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +34917792809
-
Madrid, Spania, 28222
- Rekruttering
- Hospital Puerta de Hierro ( Site 2009)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +34911916000
-
-
Barcelona
-
L'Hospitalet de Llobregat, Barcelona, Spania, 08908
- Rekruttering
- Instituto Catalan de Oncologia ICO - Hospital Duran i Reynals ( Site 2000)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +34932607750
-
-
Castille and León
-
Salamanca, Castille and León, Spania, 37007
- Rekruttering
- Hospital Universitario de Salamanca ( Site 2002)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: 34923 29 11 00x55974
-
-
La Coruna
-
A Coruña, La Coruna, Spania, 15006
- Rekruttering
- CHUAC-Complejo Hospitalario Universitario A Coruña ( Site 2005)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: 34981178000
-
-
-
-
-
Manchester, Storbritannia, M20 4BX
- Rekruttering
- The Christie NHS Foundation Trust ( Site 2602)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: 01619561217
-
-
Bristol, City of
-
Bristol, Bristol, City of, Storbritannia, BS2 8ED
- Rekruttering
- Bristol Haematology and Oncology Centre ( Site 2610)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: 01173426733
-
-
England
-
Nottingham, England, Storbritannia, NG5 1PF
- Rekruttering
- Nottingham University Hospitals NHS Trust. City Hospital Campus ( Site 2601)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +441159691169
-
Windsor, England, Storbritannia, SL4 3HD
- Rekruttering
- GenesisCare - Windsor ( Site 2608)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +447989474250
-
-
London, City of
-
London, London, City of, Storbritannia, W1G 6AD
- Rekruttering
- Sarah Cannon Research Institute UK ( Site 2612)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: 02032195234
-
-
Oxfordshire
-
Oxford, Oxfordshire, Storbritannia, OX4 6LB
- Rekruttering
- GenesisCare - Oxford ( Site 2607)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +447989474250
-
-
Suffolk
-
Newmarket, Suffolk, Storbritannia, CB8 7XN
- Rekruttering
- GenesisCare - Cambridge ( Site 2611)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: 01223 655145
-
-
Surrey
-
Sutton, Surrey, Storbritannia, SM2 5PT
- Rekruttering
- The Royal Marsden NHS Foundation Trust. ( Site 2606)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: 020 8642 6011
-
-
-
-
Canton Ticino
-
Bellinzona, Canton Ticino, Sveits, 6500
- Rekruttering
- Istituto Oncologica della Svizzera Italiana (IOSI) ( Site 2302)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +41918118540
-
-
Canton of Bern
-
Bern, Canton of Bern, Sveits, 3010
- Rekruttering
- Inselspital Bern ( Site 2303)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +41316329023
-
-
-
-
-
Seoul, Sør -Korea, 03722
- Rekruttering
- Severance Hospital Yonsei University Health System ( Site 2201)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +82222281972
-
Seoul, Sør -Korea, 06351
- Rekruttering
- Samsung Medical Center ( Site 2200)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +82234106548
-
-
-
-
-
Hradec Králové, Tsjekkia, 500 05
- Rekruttering
- Fakultni nemocnice Hradec Kralove ( Site 0601)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +420495832159
-
-
Brno-mesto
-
Brno, Brno-mesto, Tsjekkia, 625 00
- Rekruttering
- Fakultní nemocnice Brno Bohunice-Interni hematologicka a onkologicka klinika ( Site 0600)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +420532233642
-
-
-
-
-
Ankara, Tyrkia (Türkiye), 06590
- Rekruttering
- Ankara Universitesi Tip Fakultesi Cebeci Hastanesi ( Site 2400)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +903125957099
-
Istanbul, Tyrkia (Türkiye), 34365
- Fullført
- VKV Amerikan Hastanesi ( Site 2403)
-
Istanbul, Tyrkia (Türkiye), 34381
- Rekruttering
- Sisli Florence Nightingale Hastanesi ( Site 2407)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +90 542 502 50 75
-
Izmir, Tyrkia (Türkiye), 35340
- Aktiv, ikke rekrutterende
- Dokuz Eylül Üniversitesi-Hematology ( Site 2402)
-
-
Istanbul
-
Stanbul, Istanbul, Tyrkia (Türkiye), 34214
- Aktiv, ikke rekrutterende
- Mega Medipol-Hematology ( Site 2406)
-
-
-
-
Baden-Wurttemberg
-
Ulm, Baden-Wurttemberg, Tyskland, 89081
- Rekruttering
- Universitaetsklinikum Ulm. ( Site 0906)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: + 49 731 500 45901
-
-
North Rhine-Westphalia
-
Cologne, North Rhine-Westphalia, Tyskland, 50937
- Rekruttering
- Universitaetsklinikum Koeln ( Site 0901)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +4922147897046
-
Siegen, North Rhine-Westphalia, Tyskland, 57072
- Fullført
- St. Marien-Krankenhaus Siegen ( Site 0914)
-
-
Saxony
-
Dresden, Saxony, Tyskland, 01307
- Rekruttering
- Universitaetsklinikum Carl Gustav Carus ( Site 0902)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: 0049 351 458 5692
-
-
-
-
-
Kyiv, Ukraina, 03022
- Rekruttering
- National Cancer Institute ( Site 2507)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +380672091427
-
-
Cherkasy Oblast
-
Cherkassy, Cherkasy Oblast, Ukraina, 18009
- Aktiv, ikke rekrutterende
- MNPE ClinCenter of Oncology,Hematology,Transplantology and Palliative Care of CherkasyRegCouncil ( Site 2509)
-
-
Ivano-Frankivsk Oblast
-
Ivano-Frankivsk, Ivano-Frankivsk Oblast, Ukraina, 76008
- Fullført
- Communal non-profit enterprise "Regional clinical hospital o-Hematology Department ( Site 2510)
-
-
Lviv Oblast
-
Lviv, Lviv Oblast, Ukraina, 79044
- Rekruttering
- Instit. of Blood Transfusion Medicine of the National Academy ( Site 2506)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +380322352276
-
-
-
-
-
Budapest, Ungarn, 1122
- Rekruttering
- Orszagos Onkologiai Intezet ( Site 1200)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +3612248600
-
-
Baranya
-
Pécs, Baranya, Ungarn, 7624
- Rekruttering
- Pecsi Tudomanyegyetem Altalanos Orvostudomanyi Kar ( Site 1202)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +3672536000
-
-
Hajdú-Bihar
-
Debrecen, Hajdú-Bihar, Ungarn, 4032
- Rekruttering
- Debreceni Egyetem Klinikai Kozpont ( Site 1201)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +3652255196
-
-
Szabolcs-Szatmár-Bereg
-
Nyíregyháza, Szabolcs-Szatmár-Bereg, Ungarn, 4400
- Rekruttering
- Szabolcs Szatmár Bereg Vármegyei Oktatókórház ( Site 1206)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +3642599700
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 within 7 days before C1D1 (the first dose of study treatment)
- Has a life expectancy of at least 3 months, based on the investigator assessment
- Has the ability to swallow and retain oral medication
- Participants who are Hepatitis B surface antigen (HBsAg)-positive are eligible if they have received Hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load prior to randomization
- Participants with history of Hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening
- Has adequate organ function
- Male participants agree to refrain from donating sperm and agree to either remain abstinent from penile-vaginal intercourse as their preferred and usual lifestyle OR agree to use contraception, during the intervention period and for at least the time required to eliminate the study intervention after last dose of study intervention
- Female participants assigned female sex at birth who are not pregnant or breastfeeding are eligible to participate if not a participant of childbearing potential (POCBP), or if a POCBP they either use a contraceptive method that is highly effective OR remain abstinent from penile-vaginal intercourse as their preferred and usual lifestyle during the intervention period and for at least to eliminate study intervention after the last dose of study intervention
- Participants with Human immunodeficiency virus (HIV) are eligible if they meet all of the following: the CD4 count is >350 cells/uL at screening, the HIV viral load is below the detectable level, are on a stable ART regimen for at least 4 weeks prior to study entry, and are compliant with their ART
Part 1 and Part 2 (Cohorts A to C and J)
-
Has a confirmed diagnosis of Chronic lymphocytic leukemia/ Small lymphocytic lymphoma (CLL/SLL) with
- At least 2 lines of prior therapy (Part 1 only)
- Part 2 Cohort A: CLL/SLL participants who are relapsed or refractory to prior therapy with a covalent, irreversible Bruton's tyrosine kinase inhibitor (BTKi), and a B-cell lymphoma 2 inhibitor (BCL2i). CLL participants must have received and failed, been intolerant to, or determined by their treating physician to be a poor phosphoinositide 3-kinase inhibitor (PI3Ki) candidate or ineligible for a PI3Ki per local guidelines
- Part 2 Cohort B: CLL/SLL participants who are relapsed or refractory following at least 1 line of prior therapy and are BTKi treatment naive
- Part 2 Cohort C: CLL/SLL participants with 17p deletion or tumor protein p53 (TP53) mutation who are relapsed or refractory following at least 1 line of prior therapy
- Part 2 Cohort J: CLL/SLL participants whose disease relapsed or was refractory to prior therapy with a covalent/irreversible BTKi and BCL2i. NOTE: As of Protocol Amendment 09, at least 10 CLL/SLL participants whose disease relapsed or was refractory to prior therapy with a covalent/irreversible BTKi, BCL2i and noncovalent/reversible BTKi (all three classes of therapies are required) will be enrolled into Cohort J
- Has active disease for CLL/SLL clearly documented to initiate therapy
- For SLL participants in Part 2: Has evaluable core or excisional lymph node biopsy for biomarker analysis from an archival or newly obtained biopsy or bone marrow aspirate at Screening (optional for participants enrolling in Part 1)
Part 2 (Cohorts D to G)
- Has a confirmed diagnosis of and meets the following prior therapy requirements:
- Participants with Richter's transformation who are relapsed or refractory following at least 1 line of prior therapy (Cohort D)
- Participants with pathologically confirmed Mantle-cell lymphoma (MCL), documented by either overexpression of cyclin D1 or t (11;14), who are relapsed or are refractory to chemoimmunotherapy and a covalent irreversible BTKi (Cohort E)
- Participants with Marginal zone lymphoma (MZL) (including splenic, nodal, and extra nodal MZL) who are relapsed or refractory to at least one prior line of systemic therapy including an anti-CD20-based regimen
- Participants with Follicular lymphoma (FL) who are relapsed or refractory to chemoimmunotherapy and immunomodulatory agents (such as lenalidomide based regimen) (Cohort G)
- Have measurable disease defined as at least 1 lesion that can be accurately measured in at least 2 dimensions with spiral Computed tomography (CT) scan
- Has a lymph node biopsy for biomarker analysis from an archival or newly obtained biopsy or bone marrow aspirate (Cohort D) at Screening
Part 2 (Cohort H): confirmed diagnosis of Waldenström's macroglobulinemia (WM); participants who are relapsed or refractory to standard therapies for WM including chemoimmunotherapy and a covalent irreversible BTKi
- Has active disease defined as 1 of the following: systemic symptoms, physical findings, laboratory abnormalities, coexisting disease
- Has measurable disease, satisfying any of the following: at least 1 lesion that can be accurately measured in at least 2 dimensions with spiral CT scan (minimum measurement must be >15 mm in the longest diameter or >10 mm in the short axis); IgM ≥450 mg/dL; or bone marrow infiltration of 10%
- Has fresh bone marrow aspirate or a lymph node biopsy for biomarker analysis at Screening or a lymph node biopsy from an archival
Exclusion Criteria:
- Has active HBV/HCV infection (Part 1 and Part 2)
- Has a history of malignancy ≤3 years before providing documented informed consent. Participants with basal cell carcinoma of skin, squamous cell carcinoma of skin, or carcinoma in situ (e.g., breast carcinoma, cervical cancer in situ) that have undergone potential curative therapy are not excluded. Participants with low-risk, early-stage prostate cancer (T1-T2a, Gleason score ≤6, and prostate-specific antigen <10 ng/mL) either treated with definitive intent or untreated in active surveillance with SD are not excluded
- Has active central nervous system (CNS) disease
- Has an active infection requiring systemic therapy
- Has received prior systemic anti-cancer therapy within 5 half-lives or 4 weeks (if prior therapy was a monoclonal antibody) before C1D1
- Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study intervention
- Has any clinically significant gastrointestinal abnormalities that might alter absorption
- History of severe bleeding disorders
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Antall våpen
Våpen og intervensjoner
Deltakergruppe / ArmDeltakergruppe / Arm |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Eksperimentell: Nemtabrutinib
Participants receive nemtabrutinib orally once daily (QD) until progressive disease (PD) or discontinuation. |
Nemtabrutinib tablets administered orally QD.
Andre navn:
|
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Part 1: Number of participants experiencing dose-limiting toxicities (DLTs)
Tidsramme: Up to ~56 days (Cycles 1-2, cycle = 28 days)
|
DLTs will be defined as toxicities observed during the first 2 cycles (8 weeks) of Part 1 and include: Grade ≥3 nonhematologic toxicity (except Grade 3 nausea, vomiting, diarrhea, rash, fatigue, and uncontrolled hypertension which will not be considered a DLT unless lasting ≥72 hours despite optimal supportive care); Grade 4 hematologic toxicity lasting >7 days (except Grade 3 lymphocytosis, Grade 4 platelet count decreased of any duration, or Grade 3 platelet count decreased if associated with bleeding); any Grade 3 or Grade 4 nonhematologic laboratory abnormality if values result in drug-induced liver injury, or medical intervention is required, or the abnormality leads to hospitalization, or the abnormality persists for >1 week (with exceptions); missing >25% of nemtabrutinib doses as a result of drug-related adverse events (AEs) during the first 2 cycles (8 weeks); Grade 5 toxicity. |
Up to ~56 days (Cycles 1-2, cycle = 28 days)
|
|
Part 1: Number of participants experiencing adverse events (AEs)
Tidsramme: Up to ~71 months
|
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants experiencing AEs will be reported for Part 1. |
Up to ~71 months
|
|
Part 1: Number of participants discontinuing study treatment due to AEs
Tidsramme: Up to ~42 months
|
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants discontinuing study treatment due to an AE will be reported for Part 1. |
Up to ~42 months
|
|
Part 2: Objective Response Rate (ORR) per International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria 2018 as assessed by independent central review (ICR)
Tidsramme: Up to ~61 months
|
ORR per iwCLL 2018 criteria is defined as the percentage of participants achieving a complete response (CR), complete response with incomplete bone marrow recovery (CRi), nodular partial response (nPR), or partial response (PR). CR is defined as meeting the following criteria: no lymph nodes >1.5 cm, spleen size <13 cm, liver normal; no constitutional symptoms, normal lymphocyte count, platelets ≥100 x 10^9/L; hemoglobin ≥11 g/dL; and normocellular marrow (no CLL cells or B lymphoid nodules). CRi is defined as meeting CR criteria but with hypocellular bone marrow. nPR is defined as having features of CR but with lymphoid nodules in the marrow. PR is defined as ≥50% decrease in ≥2 of the following: lymph nodes, liver and/or spleen size, lymphocytes PLUS ≥1 of the following met: platelets ≥100 x 10^9/L or ≥50% increase from screening, hemoglobin >11 g/dL or ≥50% increase from screening, CLL cells or B lymphoid nodules in marrow. |
Up to ~61 months
|
|
Part 2: ORR per Lugano criteria 2014 as assessed by ICR
Tidsramme: Up to ~61 months
|
ORR per Lugano criteria 2014 is defined as the percentage of participants achieving a CR or PR. CR defined as EITHER CR by imaging (computed tomography [CT]): all lymph nodes normal (none ≥15 mm) and normal liver and spleen OR complete metabolic response (CMR): score of 1, 2 or 3 on the 5-point scale assessing fluorodeoxyglucose (FDG) metabolic activity in lymphomatous lesions (ranging from 1=no uptake above background to 5=uptake markedly higher than liver) AND bone marrow (BM) normal by morphology. PR defined as EITHER PR by imaging (CT) with ≥50% decrease in the sum of the product of diameters [SPD] of target lesions, no worsening of nontarget lesions, no new lesions and ≥50% spleen abnormal portion OR Partial Metabolic Response (PMR) with score of 4 or 5 on the FDG 5-point scale (with no new lesions) and decreased overall uptake AND residual BM abnormalities; OR CR by imaging with residual BM abnormalities; OR PR by imaging without residual BM abnormalities. |
Up to ~61 months
|
|
Part 2: ORR per International Workshop on Waldenström's Macroglobulinemia (IWWM) criteria 2014 as assessed by ICR
Tidsramme: Up to ~71 months
|
ORR per IWWM criteria 2014 is defined as the percentage of participants achieving a CR, very good partial response (VGPR), or PR. CR is defined as all lymph nodes are normal in size (none ≥15 mm), liver and spleen normal in size, serum immunoglobulin M (IgM) values in the normal range, disappearance of monoclonal protein by immunofixation (confirmation needed with a second immunofixation at any subsequent timepoint), and no histological evidence of BM involvement. VGPR is defined as ≥50% decrease from baseline in SPD of lymph nodes (if abnormal at baseline), ≥50% decrease from baseline in the abnormal portion of the spleen (if previously abnormal), and ≥90% decrease from baseline in serum IgM, or serum IgM values in normal range. PR is defined as ≥50% decrease from baseline in SPD of lymph nodes (if abnormal at baseline), ≥50% decrease from baseline in serum IgM, and ≥50% decrease from baseline in the abnormal portion of the spleen (if previously abnormal). |
Up to ~71 months
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Part 1: Area Under the Curve (AUC) of Nemtabrutinib
Tidsramme: At designated time points (up to ~57 days)
|
Blood samples will be obtained at designated time points during Part 1 for the assessment of nemtabrutinib AUC (Day 1 of Cycles 1 and 2: Pre-dose, 2, 4, 6, 8, and 24 hours post-dose; Day 1 of Cycle 3: pre-dose and 2, 4, and 6 hours post-dose [up to ~57 days]). Each cycle is 28 days. |
At designated time points (up to ~57 days)
|
|
Part 1: Minimum Concentration (Cmin) of Nemtabrutinib
Tidsramme: At designated time points (up to ~57 days)
|
Blood samples will be obtained at designated time points during Part 1 for the assessment of nemtabrutinib Cmin (Day 1 of Cycles 1 and 2: Pre-dose, 2, 4, 6, 8, and 24 hours post-dose; Day 1 of Cycle 3: pre-dose and 2, 4, and 6 hours post-dose [up to ~57 days]). Each cycle is 28 days. |
At designated time points (up to ~57 days)
|
|
Part 1: Maximum Concentration (Cmax) of Nemtabrutinib
Tidsramme: At designated time points (up to ~57 days)
|
Blood samples will be obtained at designated time points during Part 1 for the assessment of nemtabrutinib Cmax (Day 1 of Cycles 1 and 2: Pre-dose, 2, 4, 6, 8, and 24 hours post-dose; Day 1 of Cycle 3: pre-dose and 2, 4, and 6 hours post-dose [up to ~57 days]). Each cycle is 28 days. |
At designated time points (up to ~57 days)
|
|
Part 1: ORR per iwCLL criteria 2018 as assessed by ICR
Tidsramme: Up to ~71 months
|
ORR per iwCLL 2018 criteria is defined as the percentage of participants achieving a CR, CRi, nPR, or PR. CR is defined as meeting the following criteria: no lymph nodes >1.5 cm, spleen size <13 cm, liver normal; no constitutional symptoms, normal lymphocyte count, platelets ≥100 x 10^9/L; hemoglobin ≥11 g/dL; and normocellular marrow (no CLL cells or B lymphoid nodules). CRi is defined as meeting CR criteria but with hypocellular bone marrow. nPR is defined as having features of CR but with lymphoid nodules in the marrow. PR is defined as ≥50% decrease in ≥2 of the following: lymph nodes, liver and/or spleen size, lymphocytes PLUS ≥1 of the following met: platelets ≥100 x 10^9/L or ≥50% increase from screening, hemoglobin >11 g/dL or ≥50% increase from screening, CLL cells or B lymphoid nodules in marrow. |
Up to ~71 months
|
|
Part 1: Duration of Response (DOR) per iwCLL criteria 2018 as assessed by ICR
Tidsramme: Up to ~71 months
|
For participants with CR, CRi, nPR, or PR per iwCLL 2018 criteria, DOR is defined as the time from the first documented evidence of objective response until PD or death due to any cause, whichever occurs first. CR is defined as meeting the following criteria: no lymph nodes >1.5 cm, spleen size <13 cm, liver normal; no constitutional symptoms, normal lymphocyte count, platelets ≥100 x 10^9/L; hemoglobin ≥11 g/dL; and normocellular marrow (no CLL cells or B lymphoid nodules). CRi is defined as meeting CR criteria but with hypocellular bone marrow. nPR is defined as having features of CR but with lymphoid nodules in the marrow. PR is defined as ≥50% decrease in ≥2 of the following: lymph nodes, liver and/or spleen size, lymphocytes PLUS ≥1 of the following met: platelets ≥100 x 10^9/L or ≥50% increase from screening, hemoglobin >11 g/dL or ≥50% increase from screening, CLL cells or B lymphoid nodules in marrow. |
Up to ~71 months
|
|
Part 2: Number of participants experiencing AEs
Tidsramme: Up to ~61 months
|
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants experiencing AEs will be reported for Part 2. |
Up to ~61 months
|
|
Part 2: Number of participants discontinuing study treatment due to AEs
Tidsramme: Up to ~42 months
|
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants discontinuing study treatment due to an AE will be reported for Part 2. |
Up to ~42 months
|
|
Part 2: AUC of Nemtabrutinib
Tidsramme: At designated time points (up to ~57 days)
|
Blood samples will be obtained at designated time points during Part 2 for the assessment of nemtabrutinib AUC (Day 1 of Cycles 1, 2, and 3: Pre-dose, 2, 4, 6, hours post-dose [up to ~57 days]). Each cycle is 28 days. |
At designated time points (up to ~57 days)
|
|
Part 2: Cmin of Nemtabrutinib
Tidsramme: At designated time points (up to ~57 days)
|
Blood samples will be obtained at designated time points during Part 2 for the assessment of nemtabrutinib Cmin (Day 1 of Cycles 1, 2, and 3: Pre-dose, 2, 4, 6, hours post-dose [up to ~57 days]). Each cycle is 28 days. |
At designated time points (up to ~57 days)
|
|
Part 2: Cmax of Nemtabrutinib
Tidsramme: At designated time points (up to ~57 days)
|
Blood samples will be obtained at designated time points during Part 2 for the assessment of nemtabrutinib Cmax (Day 1 of Cycles 1, 2, and 3: Pre-dose, 2, 4, 6, hours post-dose [up to ~57 days]). Each cycle is 28 days. |
At designated time points (up to ~57 days)
|
|
Part 2: DOR per iwCLL criteria 2018 as assessed by ICR
Tidsramme: Up to ~61 months
|
For participants with CR, CRi, nPR, or PR per iwCLL 2018 criteria, DOR is defined as the time from the first documented evidence of objective response until disease progression or death due to any cause, whichever occurs first. CR is defined as meeting the following criteria: no lymph nodes >1.5 cm, spleen size <13 cm, liver normal; no constitutional symptoms, normal lymphocyte count, platelets ≥100 x 10^9/L; hemoglobin ≥11 g/dL; and normocellular marrow (no CLL cells or B lymphoid nodules). CRi is defined as meeting CR criteria but with hypocellular bone marrow. nPR is defined as having features of CR but with lymphoid nodules in the marrow. PR is defined as ≥50% decrease in ≥2 of the following: lymph nodes, liver and/or spleen size, lymphocytes PLUS ≥1 of the following met: platelets ≥100 x 10^9/L or ≥50% increase from screening, hemoglobin >11 g/dL or ≥50% increase from screening, CLL cells or B lymphoid nodules in marrow. |
Up to ~61 months
|
|
Part 2: DOR per Lugano criteria 2014 as assessed by ICR
Tidsramme: Up to ~61 months
|
For participants with CR or PR per Lugano criteria 2014, DOR is defined as the time from the first documented evidence of objective response until PD or death due to any cause, whichever occurs first. CR defined as EITHER CR by imaging (CT): all lymph nodes normal (none ≥15 mm) and normal liver and spleen OR CMR: score of 1, 2 or 3 on the 5-point scale assessing FDG metabolic activity in lymphomatous lesions (ranging from 1=no uptake above background to 5=uptake markedly higher than liver and/or new lesions) AND BM normal by morphology. PR defined as EITHER PR by imaging (CT) with ≥50% decrease in the SPD of target lesions, no worsening of nontarget lesions, no new lesions and ≥50% spleen abnormal portion OR PMR with score of 4 or 5 on the FDG 5-point scale (with no new lesions) and decreased overall uptake AND residual BM abnormalities; OR CR by imaging with residual BM abnormalities; OR PR by imaging without residual BM abnormalities. |
Up to ~61 months
|
|
Part 2: DOR per IWWM criteria 2014 as assessed by ICR
Tidsramme: Up to ~61 months
|
For participants with CR, VGPR, or PR per IWWM criteria 2014, DOR defined as the time from first documented evidence of objective response until PD or death due to any cause, whichever occurs first. CR defined as all lymph nodes normal in size (none ≥15 mm), liver and spleen normal in size, serum IgM values in normal range, disappearance of monoclonal protein by immunofixation (confirmation needed with second immunofixation at any subsequent timepoint), and no histological evidence of BM involvement. VGPR defined as ≥50% decrease from baseline in SPD of lymph nodes (if abnormal at baseline), ≥50% decrease from baseline in abnormal portion of the spleen (if previously abnormal), and ≥90% decrease from baseline in serum IgM, or serum IgM values in normal range. PR is defined as ≥50% decrease from baseline in SPD of lymph nodes (if abnormal at baseline), ≥50% decrease from baseline in serum IgM, and ≥50% decrease from baseline in abnormal portion of the spleen (if previously abnormal). |
Up to ~61 months
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Etterforskere
Etterforskere
- Studieleder: Medical Director, Merck Sharp & Dohme LLC
Publikasjoner og nyttige lenker
Hjelpsomme linker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Studiestart
Primær fullføring (Antatt)
Primær fullføring
Studiet fullført (Antatt)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Vaskulære sykdommer
- Kardiovaskulære sykdommer
- Neoplasmer etter nettsted
- Neoplasmer
- Sykdommer i immunsystemet
- Neoplasmer etter histologisk type
- Hematologiske sykdommer
- Lymfesykdommer
- Lymfoproliferative lidelser
- Immunproliferative lidelser
- Lymfom
- Neoplasmer, plasmacelle
- Hemostatiske lidelser
- Paraproteinemier
- Blodproteinforstyrrelser
- Hemoragiske lidelser
- Leukemi, lymfoid
- Leukemi
- Hemic og lymfatiske sykdommer
- Hematologiske neoplasmer
- Lymfom, Non-Hodgkin
- Waldenstrom makroglobulinemi
- Leukemi, B-celle
- ARQ531
Andre studie-ID-numre
Andre studie-ID-numre
- 1026-003
- MK-1026-003 (Annen identifikator: MSD)
- 2020-002324-36 (EudraCT-nummer)
- U1111-1290-4004 (Registeridentifikator: UTN)
- 2023-504931-42-00 (Registeridentifikator: EU CT)
- 2023 (U.S. NIH-stipend/kontrakt)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .